Molecular Partners AG (MOLN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Molecular Partners AG (MOLN) has a cash flow conversion efficiency ratio of -0.099x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-9.49 Million ≈ $-12.00 Million USD) by net assets (CHF95.53 Million ≈ $120.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MOLN cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Molecular Partners AG - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Molecular Partners AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Molecular Partners AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Molecular Partners AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank Bumi Arta Tbk
JK:BNBA
|
-0.228x |
|
Cegedim S.A.
PA:CGM
|
0.260x |
|
Cash Converters International
AU:CCV
|
0.102x |
|
Interflex Co. Ltd
KQ:051370
|
0.017x |
|
Tavia Acquisition Corp. Unit
NASDAQ:TAVIU
|
-0.001x |
|
JF Technology BHD
KLSE:0146
|
0.023x |
|
Votum SA
WAR:VOT
|
0.078x |
|
Mikro MSC Bhd
KLSE:0112
|
0.019x |
Annual Cash Flow Conversion Efficiency for Molecular Partners AG (2013–2024)
The table below shows the annual cash flow conversion efficiency of Molecular Partners AG from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Molecular Partners AG (MOLN) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF141.64 Million ≈ $179.07 Million |
CHF-59.25 Million ≈ $-74.91 Million |
-0.418x | -25.08% |
| 2023-12-31 | CHF176.43 Million ≈ $223.05 Million |
CHF-59.01 Million ≈ $-74.60 Million |
-0.334x | -166.33% |
| 2022-12-31 | CHF235.17 Million ≈ $297.31 Million |
CHF118.57 Million ≈ $149.90 Million |
0.504x | +159.47% |
| 2021-12-31 | CHF107.29 Million ≈ $135.64 Million |
CHF-90.95 Million ≈ $-114.99 Million |
-0.848x | -213.61% |
| 2020-12-31 | CHF107.22 Million ≈ $135.56 Million |
CHF-28.98 Million ≈ $-36.64 Million |
-0.270x | -1130.82% |
| 2019-12-31 | CHF54.14 Million ≈ $68.45 Million |
CHF-1.19 Million ≈ $-1.50 Million |
-0.022x | +95.26% |
| 2018-12-31 | CHF91.70 Million ≈ $115.94 Million |
CHF-42.47 Million ≈ $-53.70 Million |
-0.463x | -35.09% |
| 2017-12-31 | CHF116.73 Million ≈ $147.58 Million |
CHF-40.02 Million ≈ $-50.60 Million |
-0.343x | -31.60% |
| 2016-12-31 | CHF135.79 Million ≈ $171.68 Million |
CHF-35.38 Million ≈ $-44.73 Million |
-0.261x | -249.27% |
| 2015-12-31 | CHF151.79 Million ≈ $191.91 Million |
CHF26.50 Million ≈ $33.50 Million |
0.175x | +328.68% |
| 2014-12-31 | CHF148.48 Million ≈ $187.72 Million |
CHF-11.33 Million ≈ $-14.33 Million |
-0.076x | +72.91% |
| 2013-12-31 | CHF48.32 Million ≈ $61.08 Million |
CHF-13.61 Million ≈ $-17.21 Million |
-0.282x | -- |
About Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more